Corporate digest
GIC
GIC has joined a consortium of institutional investors, led by Hillhouse Capital Group, to invest around US$418 million through a private placement in Nasdaq-listed I-Mab, a clinical stage biopharmaceutical company.
I-Mab is committed to the discovery, development and commercialisation of novel biologics, and intends to use the placement proceeds to fund ongoing and planned research and clinical programmes globally.
Decoding Asia newsletter: your guide to navigating Asia in a new global order. Sign up here to get Decoding Asia newsletter. Delivered to your inbox. Free.
Copyright SPH Media. All rights reserved.